Key result
Anthocyanin intake cuts ADP-induced platelet aggregation by up to ~29% vs. control.
Why the study?
The precise effects of anthocyanin-rich diets and supplements on platelet aggregation, a key factor in thrombotic risk, are not fully comprehended.
Do anthocyanin-rich interventions reduce platelet aggregation in adult humans?
Systematic Review (n=165)
Do anthocyanin-rich interventions reduce platelet aggregation in adult humans?
Anthocyanin-rich diets and supplements, particularly at doses ≥320 mg/day, may reduce ADP- and collagen-induced platelet aggregation, suggesting a potential dietary approach to lower thrombotic risk.
Supports adjunctive antiplatelet effects in overweight or dyslipidemic adults; extends epidemiological CVD protection data with RCT platelet evidence.
Anthocyanins, a subclass of dietary flavonoids prevalent in fruits and vegetables, have been linked to a diminished risk of cardiovascular disease (CVD) in epidemiological research. Nonetheless, their precise effects on platelet aggregation, a crucial factor in thrombotic risk, are not fully comprehended. This systematic study sought to assess the effects of anthocyanin-rich diets and supplements on platelet function in adult humans. A comprehensive search of PubMed and Web of Science was performed to identify randomised controlled trials (RCTs) published until July 2024, with a subsequent search in October 2025. English-language RCTs involving adults between the ages of 20 and 65 that reported specific anthocyanin dosage and looked at how anthocyanin treatments affected platelet aggregation were eligible. Study design, demographic characteristics, intervention specifics, and platelet-related outcomes were all extracted. Risk of bias was assessed using the Cochrane RoB 2 tool. Six randomised controlled trials fulfilled the inclusion criteria. Anthocyanin consumption was consistently linked to decreased platelet aggregation produced by adenosine diphosphate (ADP) and collagen in comparison to control interventions. Increased consumption levels (≥ 320 mg/day), especially in extract or juice form, correlated with enhanced benefits, indicating a possible dose–response relationship. Reductions of up to 29% in ADP-induced aggregation and 17% in collagen-induced aggregation were observed. The effects were more significant in metabolically at-risk populations, such as those with overweight/obesity or dyslipidaemia, whereas control groups exhibited minor or no alterations. Current evidence indicates that meals and supplements high in anthocyanins may influence platelet function and decrease thrombotic risk. However, small sample sizes, inconsistent study designs, and variations in anthocyanin formulations and bioavailability restrict the strength of the data. To verify therapeutic relevance and determine the best intake regimens, more carefully planned, sufficiently powered, long-term RCTs including a variety of groups are needed.
No takes yet. Share an insight, caveat, or question.
Khani et al. (2026) conducted a systematic review in Healthy and metabolically at-risk adults (n=165). Anthocyanin-rich diets and supplements vs. Control interventions (placebo or low-anthocyanin foods) was evaluated on Platelet aggregation (ADP- and collagen-induced). Anthocyanin consumption, especially at doses of 320 mg/day or more, reduced ADP-induced platelet aggregation by up to 29% and collagen-induced aggregation by up to 17% compared to control interventions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: